Recently Updated Guidelines

Guidelines for Treatment of Cancer by Type

Central Nervous System Cancers Version 3.2024
Cervical Cancer Version 4.2024
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 1.2025
Hairy Cell Leukemia Version 1.2025
Hepatocellular Carcinoma Version 3.2024
Melanoma: Cutaneous Version 3.2024
Mesothelioma: Peritoneal Version 3.2024
Mesothelioma: Pleural Version 2.2024
Multiple Myeloma Version 1.2025
Non-Small Cell Lung Cancer Version 10.2024
Occult Primary Version 2.2025
Small Bowel Adenocarcinoma Version 5.2024
Soft Tissue Sarcoma Version 3.2024
Systemic Light Chain Amyloidosis Version 1.2025
Uterine Neoplasms Version 3.2024
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Version 1.2025

NCCN Guidelines with Evidence Blocks - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 1.2025
NCCN Guidelines with Evidence Blocks - Hepatocellular Carcinoma Version 3.2024
NCCN Guidelines with Evidence Blocks - Multiple Myeloma Version 1.2025
NCCN Guidelines with Evidence Blocks - Non-Small Cell Lung Cancer Version 10.2024
NCCN Guidelines with Evidence Blocks - Occult Primary Version 2.2025
NCCN Guidelines with Evidence Blocks - Small Bowel Adenocarcinoma Version 5.2024
NCCN Guidelines with Evidence Blocks - Soft Tissue Sarcoma Version 3.2024
NCCN Guidelines with Evidence Blocks - Systemic Light Chain Amyloidosis Version 1.2025
NCCN Guidelines with Evidence Blocks - Uterine Neoplasms Version 3.2024
NCCN Guidelines with Evidence Blocks - Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Version 1.2025

Guidelines for Detection, Prevention, & Risk Reduction

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 1.2025
Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric Version 2.2024

Guidelines for Supportive Care

Antiemesis Version 2.2024
Prevention and Treatment of Cancer-Related Infections Version 3.2024

Guidelines for Specific Populations

Adolescent and Young Adult (AYA) Oncology Version 2.2025